Biotech company BioMarin Pharmacuetical’s shares are moving sharply higher on heavy volume in Friday’s session. This on talk that French pharmaceutical giant, Sanofi might be looking to buy the orphan drugmaker. Financial blog Betaville reports that Sanofi has shifted its focus to BioMarin, frustrated after its advances for Medivation have been rejected. But TheStreet’s Alicia McElhaney says the talk may be nothing more than just that. Jeanne Yurman reports.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
